Eribulin

HALAVEN®

About HALAVEN®

  1. Marketed by Eisai Inc.
  2. Microtubule dynamics inhibitor
  3. Treatment of refractory, metastatic breast cancer and liposarcoma

Approvals

  1. First U.S. approval: November 15, 2010
  2. First E.U. approval: March 17, 2011

Constraint date forecast:

  1. Patent expiry: 2023 (United States)
  2. SPC expiry: 2024 (European Union)
  3. Patent expiry: 2024 (Japan)

API availability

Source: Cortellis Generics Intelligence

The future of the generics landscape

Drugs to Watch

BROVANA®

Arformoterol tartrate
Respiratory - chronic obstructive pulmonary disease
Drugs to Watch

CALQUENCE®

Acalabrutinib
Oncology
Drugs to Watch

GILOTRIF®

Afatinib Dimaleate
Antineoplastic landscape
Drugs to Watch

HALAVEN®

Eribulin
Antineoplastic landscape
Drugs to Watch

HUMIRA®

Adalimumab
Excessive immune response/autoimmunity
Drugs to Watch

ICLUSIG®

Ponatinib Hydrochloride
Antineoplastic landscape
Drugs to Watch

JANUVIA®

Sitagliptin phosphate
Endocrine - type 2 diabetes
Drugs to Watch

LYNPARZA®

Olaparib
Antineoplastic landscape
Drugs to Watch

TASIGNA®

Nilotinib Hydrochloride
Antineoplastic landscape
Drugs to Watch

VEMLIDY®

Tenofovir Alafenamide
Infectious disease
Drugs to Watch

VOTRIENT®

Pazopanib
Antineoplastic landscape
Drugs to Watch

XARELTO®

Rivaroxaban
Cardiovascular disease

From innovation to bottom line

Access our global intelligence, advanced analytics and global team of experts.

Contact our team